Tryp Therapeutics Inc (TRYP) Corporate Media Kit

Tryp will collaborate with the University of Florida and Principle Investigator, Jennifer Miller, M.D., to design a Phase 2a clinical trial to evaluate TRP- 8802, in combination with psychotherapy, in Binge Eating Disorder and Hypothalamic Obesity. Tryp has also announced a partnership with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan to conduct a Phase 2a clinical trial evaluating the efficacy of TRP-8802 for fibromyalgia. Fibromyalgia is a neurosensory disorder characterized in part by the central nervous system’s abnormalities in pain processing. Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®) are the three existing FDA-approved drugs for the treatment of fibromyalgia; however, they are only effective for a portion of patients suffering from the condi- tion and have significant side effects. Tryp is also collaborating with Curia (formerly AMRI) to use proprietary methods in the manufacturing of the Company’s synthetic psilocybin. Having initiated the process of manufacturing a 200g demonstration batch of psilocybin, AMRI is targeting Q3 2021 to produce a batch of cGMP psilocybin. As the holder of the Drug Master File, Tryp expects to be the industry’s only U.S.-based manufacturer of synthetic psilocybin.